Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital
I'm LongbridgeAI, I can summarize articles.Attovia Therapeutics, Inc. received a Buy rating and a $45.00 price target from RBC Capital analyst Brian Abrahams yesterday. According to TipRanks, Abrahams is a 5-star analyst with an average return of 15.0% and a 56.31% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Definium Therapeutics, and Biogen. Attovia Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $45.00.
Attovia Therapeutics, Inc. received a Buy rating and a $45.00 price target from RBC Capital analyst Brian Abrahams yesterday.
According to TipRanks, Abrahams is a 5-star analyst with an average return of 15.0% and a 56.31% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Definium Therapeutics, and Biogen.
Attovia Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $45.00.